arrow_back Back to App

Expanded Pediatric Cancer Drug Testing and Rare Disease Incentive Extension.

This law expands the requirement for testing new cancer drugs on children if the drug's molecular target is relevant to pediatric cancers. Furthermore, it extends the incentive program (priority review vouchers) for pharmaceutical companies developing treatments for rare pediatric diseases until 2030. The goal is to accelerate access to safe and effective therapies for the youngest patients suffering from serious conditions.
Key points
Companies introducing new adult cancer drugs must now study their use in children, including in combination with existing standard-of-care treatments, if the molecular target is relevant to pediatric cancers.
The program rewarding companies for developing rare pediatric disease drugs (via expedited review of other drugs) is extended until September 2030.
The changes aim to increase the amount of clinical data available regarding the dosing and safety of cancer drugs for different pediatric age groups.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_3302
Sponsor: Sen. Mullin, Markwayne [R-OK]
Process start date: 2025-12-02
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Mikaela Naylon Give Kids a Chance Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_3302.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-12-02.

What are the main provisions?

Key points include:

  • Companies introducing new adult cancer drugs must now study their use in children, including in combination with existing standard-of-care treatments, if the molecular target is relevant to pediatric cancers.
  • The program rewarding companies for developing rare pediatric disease drugs (via expedited review of other drugs) is extended until September 2030.
  • The changes aim to increase the amount of clinical data available regarding the dosing and safety of cancer drugs for different pediatric age groups.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Mullin, Markwayne [R-OK].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health